JWJoshua D. Webster

Joshua D. Webster

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joshua D. Webster has a total of 198 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A multi-voiced perspective on opportunities, challenges, boundaries, and forecasts of artificial intelligence in veterinary pathology

    by Christof A. Bertram, Jennifer J. Antonythasan, Bhupinder Bawa, Candice P. Chu, Kara N. Corps, Michael Fitzke, Jodie Gerdin, Dominik Hirling, Andrew Janowczyk, Robert Klopfleisch, et al.

  • Open Access

    Genetic decoupling of NINJ1-mediated cell lysis from developmental hydrocephalus reveals the physiological role of the α1 domain

    by Nobuhiko Kayagaki, Bettina Lee, Irma Stowe, Juan Zhang, John Liu, Wyne Lee, Fermin Gallardo-Chang, Joshua Webster, Lisa Miosge, Edward Bertram

    NINJ1, a cell surface protein, mediates plasma membrane rupture (PMR) in cells undergoing pyroptosis or other form of cell death. Catastrophic PMR releases proinflammatory cytoplasmic molecules termed damage-associated molecular patterns (DAMPs). Some mice with Ninj1-deficient alleles (Ninj1−/−) die perinatally due to developmental hydrocephalus with variable frequency. While Ninj1−/− mice are invaluable for studying cell lysis, their utility especially in large-scale in vivo disease models has been severely bottlenecked by this sporadic hydrocephalus. Using novel knock-in mouse models, we show under physiological conditions that the conserved, N-terminal amphipathic α1 domain of NINJ1 is strictly required for PMR, yet completely dispensable for embryonic development. Ninj1K45Q/K45Q, harboring a point mutation in the α1 domain, resembles Ninj1 deficiency by attenuating PMR in cultured bone marrow-derived macrophages (BMDMs) and liver injury in vivo. In contrast, Ninj2−/− alleles or Ninj1W29A/W29A alleles that encode a point mutation in a reported adhesion segment of the N-terminus region, exhibit unaltered PMR in BMDMs. Crucially, unlike Ninj1−/− animals, Ninj1K45Q/K45Q mice and Ninj1W29A/W29A mice exhibit normal Mendelian survival and are free from developmental hydrocephalus. Our genetic findings decouple the lytic function of NINJ1 from its homeostatic role in development, establishing Ninj1K45Q/K45Q mice as a powerful, hydrocephalus-free resource to accelerate in vivo and in vitro investigations of PMR and inflammatory diseases.

  • Open Access

    Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model

    by Thijs J. Hagenbeek, Jason Zbieg, Russell Smith, Sayantanee Paul, Luca Gerosa, Consuelo Torrini, Alissa D. Guarnaccia, Christy Ong, Jennifer A. Lacap, Miaoran Ning, et al.

    TEAD transcription factors enable the oncogenic activity of deregulated Hippo signaling and are a promising therapeutic target in oncology. Targeting the TEAD lipid pocket is an established path to inhibit the oncogenic activities of cofactors YAP and TAZ. Here we present two pan-TEAD inhibitors, GNE-8025 and its in vivo brain-penetrant derivative GNE-2181, that covalently bind the lipid pocket at a conserved cysteine. Both small molecules show growth inhibition of YAP-driven tumor cells in vitro and in vivo. Moreover, we show that GNE-8025 increases the activity of a broad range of MAPK pathway inhibitors in vitro as well as the KRASG12C inhibitor Divarasib both in vitro and in vivo. In addition, GNE-2181 inhibits growth of an intracranial tumor model in vivo. Altogether we present a next-generation class of TEAD inhibitors representing a significant advancement towards potent, specific, and effective Hippo-targeting cancer therapies.


  • Open Access

    cFLIP suppresses caspase-1- and MLKL-independent perinatal lethality driven by auto-processing impaired caspase-8 D387A

    by Kim Newton, Katherine E. Wickliffe, Allie Maltzman, Debra L. Dugger, Juan Reyes Jr, Natasha Bacarro, Søren Warming, Neha Rohatgi, Rohit Reja, Joshua D. Webster, et al.

    Death ligands, including FAS ligand (FASL) and tumor necrosis factor (TNF), trigger apoptosis by promoting caspase-8 dimerization and activation. Impaired FAS signaling causes unconventional lymphocytes to accumulate, resulting in lymphadenopathy. Although autoprocessing of caspase-8 is considered important for apoptosis, autoprocessing-deficient Casp8 D387A/D387A mice do not develop lymphadenopathy. We show that this is because heterodimers of caspase-8 D387A and cFLIP, besides suppressing MLKL-driven necroptosis, can also induce apoptosis. Interestingly, caspase-8 D387A elicited MLKL- and caspase-1-independent intestinal atrophy and perinatal lethality in mice lacking cFLIP. Caspase-8 D387A interacted with FADD and RIPK1 in the intestine, where there was aberrant cleavage of N4BP1 and caspase-3, plus enhanced NF-κB signaling. Eliminating FADD, the adaptor protein that promotes caspase-8 oligomerization, prevented this perinatal lethality. Collectively, our results suggest that cFLIP forms heterodimers with caspase-8 D387A to promote apoptosis in some contexts, while limiting the activity of caspase-8 D387A homodimers in others.


  • Reviewer-in-training: A mentoring opportunity in the peer review process

    by Joshua D. Webster, Patricia Pesavento

  • Reporting guidelines for manuscripts that use artificial intelligence–based automated image analysis in Veterinary Pathology

    by Christof A. Bertram, Melissa Schutten, Lorenzo Ressel, Katharina Breininger, Joshua D. Webster, Marc Aubreville


  • Open Access

    RIP1 inhibition protects retinal ganglion cells in glaucoma models of ocular injury

    by Bo Kyoung Kim, Tatiana Goncharov, Sébastien A. Archaimbault, Filip Roudnicky, Joshua D. Webster, Peter D. Westenskow, Domagoj Vucic

    Receptor-interacting protein 1 (RIP1, RIPK1) is a critical mediator of multiple signaling pathways that promote inflammatory responses and cell death. The kinase activity of RIP1 contributes to the pathogenesis of a number of inflammatory and neurodegenerative diseases. However, the role of RIP1 in retinopathies remains unclear. This study demonstrates that RIP1 inhibition protects retinal ganglion cells (RGCs) in preclinical glaucoma models. Genetic inactivation of RIP1 improves RGC survival and preserves retinal function in the preclinical glaucoma models of optic nerve crush (ONC) and ischemia–reperfusion injury (IRI). In addition, the involvement of necroptosis in ONC and IRI glaucoma models was examined by utilizing RIP1 kinase-dead (RIP1-KD), RIP3 knockout (RIP3-KO), and MLKL knockout (MLKL-KO) mice. The number of RGCs, retinal thickness, and visual acuity were rescued in RIP1-kinase-dead (RIP1-KD) mice in both models, while wild-type (WT) mice experienced significant retinal thinning, RGC loss, and vision impairment. RIP3-KO and MLKL-KO mice showed moderate protective effects in the IRI model and limited in the ONC model. Furthermore, we confirmed that a glaucoma causative mutation in optineurin, OPTN-E50K, sensitizes cells to RIP1-mediated inflammatory cell death. RIP1 inhibition reduces RGC death and axonal degeneration following IRI in mice expressing OPTN-WT and OPTN-E50K variant mice. We demonstrate that RIP1 inactivation suppressed microglial infiltration in the RGC layer following glaucomatous damage. Finally, this study highlights that human glaucomatous retinas exhibit elevated levels of TNF and RIP3 mRNA and microglia infiltration, thus demonstrating the role of neuroinflammation in glaucoma pathogenesis. Altogether, these data indicate that RIP1 plays an important role in modulating neuroinflammation and that inhibiting RIP1 activity may provide a neuroprotective therapy for glaucoma.


  • Diffusion tensor MRI is sensitive to fibrotic injury in a mouse model of oxalate-induced chronic kidney disease

    by Rohan S. Virgincar, Aaron K. Wong, Kai H. Barck, Joshua D. Webster, Jeffrey Hung, Patrick Caplazi, Man Kin Choy, William F. Forrest, Laura C. Bell, Alex J. de Crespigny, et al.

    Chronic kidney disease (CKD) can be characterized by inflammation and fibrosis of the kidney. Although standard of care methods have been limited in scope, safety, and spatial distribution, MRI diffusion tensor imaging (DTI) has emerged as a promising noninvasive technology to evaluate renal fibrosis in vivo. In this study, we performed DTI in an oxalate mouse model of CKD to systematically identify local kidney injury. DTI parameters strongly correlated with histology, blood biomarkers, hydroxyproline, and gene expression.


  • Open Access

    ZBP1 and TRIF trigger lethal necroptosis in mice lacking caspase-8 and TNFR1

    by Margaret Solon, Nianfeng Ge, Shannon Hambro, Susan Haller, Jian Jiang, Miriam Baca, Jessica Preston, Allie Maltzman, Katherine E. Wickliffe, Yuxin Liang, et al.

    Necroptosis is a lytic form of cell death that is mediated by the kinase RIPK3 and the pseudokinase MLKL when caspase-8 is inhibited downstream of death receptors, toll-like receptor 3 (TLR3), TLR4, and the intracellular Z-form nucleic acid sensor ZBP1. Oligomerization and activation of RIPK3 is driven by interactions with the kinase RIPK1, the TLR adaptor TRIF, or ZBP1. In this study, we use immunohistochemistry (IHC) and in situ hybridization (ISH) assays to generate a tissue atlas characterizing RIPK1, RIPK3, Mlkl, and ZBP1 expression in mouse tissues. RIPK1, RIPK3, and Mlkl were co-expressed in most immune cell populations, endothelial cells, and many barrier epithelia. ZBP1 was expressed in many immune populations, but had more variable expression in epithelia compared to RIPK1, RIPK3, and Mlkl. Intriguingly, expression of ZBP1 was elevated in Casp8−/−Tnfr1−/− embryos prior to their succumbing to aberrant necroptosis around embryonic day 15 (E15). ZBP1 contributed to this embryonic lethality because rare Casp8−/−Tnfr1−/−Zbp1−/− mice survived until after birth. Necroptosis mediated by TRIF contributed to the demise of Casp8−/−Tnfr1−/−Zbp1−/− pups in the perinatal period. Of note, Casp8−/−Tnfr1−/−Trif−/−Zbp1−/− mice exhibited autoinflammation and morbidity, typically within 5–7 weeks of being born, which is not seen in Casp8−/−Ripk1−/−Trif−/−Zbp1−/−, Casp8−/−Ripk3−/−, or Casp8−/−Mlkl−/− mice. Therefore, after birth, loss of caspase-8 probably unleashes RIPK1-dependent necroptosis driven by death receptors other than TNFR1.


  • Open Access

    Caspase cleavage of RIPK3 after Asp333 is dispensable for mouse embryogenesis

    by Kim Newton, Katherine E. Wickliffe, Allie Maltzman, Debra L. Dugger, Joshua D. Webster, Hongyan Guo, Vishva M. Dixit

    The proteolytic activity of caspase-8 suppresses lethal RIPK1-, RIPK3- and MLKL-dependent necroptosis during mouse embryogenesis. Caspase-8 is reported to cleave RIPK3 in addition to the RIPK3-interacting kinase RIPK1, but whether cleavage of RIPK3 is crucial for necroptosis suppression is unclear. Here we show that caspase-8-driven cleavage of endogenous mouse RIPK3 after Asp333 is dependent on downstream caspase-3. Consistent with RIPK3 cleavage being a consequence of apoptosis rather than a critical brake on necroptosis, Ripk3D333A/D333A knock-in mice lacking the Asp333 cleavage site are viable and develop normally. Moreover, in contrast to mice lacking caspase-8 in their intestinal epithelial cells, Ripk3D333A/D333A mice do not exhibit increased sensitivity to high dose tumor necrosis factor (TNF). Ripk3D333A/D333A macrophages died at the same rate as wild-type (WT) macrophages in response to TNF plus cycloheximide, TNF plus emricasan, or infection with murine cytomegalovirus (MCMV) lacking M36 and M45 to inhibit caspase-8 and RIPK3 activation, respectively. We conclude that caspase cleavage of RIPK3 is dispensable for mouse development, and that cleavage of caspase-8 substrates, including RIPK1, is sufficient to prevent necroptosis.